Understanding Competition in U.S. Prescription Drug Markets: Entry and Supply Chain Dynamics #00230

Submission Number:
00230
Commenter:
H. Lloyd Holston
State:
Mississippi
Initiative Name:
Understanding Competition in U.S. Prescription Drug Markets: Entry and Supply Chain Dynamics
I own and operate an independent retail pharmacy. Pharmacy Benefit Managers are taking DIR fees ($27,432 from my Pharmacy for 2 quarters in 2017) which are negatively affecting our and every independent retail pharmacy's ability to remain in business. Prime Therapeutics, one of the large PBM's, actually PROFITED from my store the first quarter of 2017. President Trump's administration is on the verge of passing an incredible tax reduction bill; DIR fees amount to a tax on my business that no other retail operation has to endure, and is grossly unfair to small Pharmacy entrepreneurs. Thank you.